Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

A Big Year In Biotech Was A Windfall For Top IPO Lawyers Laser-Focused On The Space (Business Insider)

Related Content

Which Jobs More Frequently Require Non-Compete Agreements?

FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars

Accord BioPharma, Inc. Announces FDA Approval of HERCESSI (trastuzumab-strf)

PTAB Issues Final Written Decisions Finding Claims of Recombinant Lentiviral Vector Patents Valid

FDA Issues Final Rule on Regulation of Laboratory Developed Tests

Biosimilar Approval Updates in Europe and China

GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech for Infringing mRNA Vaccine Patents

Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR

BridgeBio Oncology Therapeutics Completes $200 Million Private Financing

Goodwin Bolsters Leading Life Sciences Practice with Partner Michael Siekman in Boston

Delphia Therapeutics Completes $67 Million Series A

Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Amid Continued Growth in the United Kingdom, Goodwin Relocates London Office to Iconic Paternoster Square

Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments

PowerUp 4 - Omer Tene (Spotify)

Life Sciences

Technology

Capital Markets